July 2018 – Maas Biolab

Helmuth von Moltke Elected to Maas Biolab Board

maasbiolab
July 2, 2018
2018
0 Comments

Santa Fe, N.M. --- July 2, 2018 ---Maas Biolab, LLC has announced that Helmuth von Moltke has been elected to the Maas Biolab Board of Managers for a new term after having previously served from the inception of the company until 2012. Mr. von Moltke is one of the nine founders of…

Maas Biolab Twitter FeedFollow

Retweet on Twitter Maas Biolab Retweeted

LREsystem Ltd @LREsystem·

1 Feb

It's back! the first of the new LRE system procedure undertaken in Ypres, Belgium.
LREsystem Ltd, bringing more power to your elbow by restoring elbow anatomy. Do not remove bone, instead, resurface, realign and restore the normal anatomy to remove all pain.

Reply on Twitter Retweet on Twitter2 Like on Twitter1 Twitter

Maas Biolab @MaasBiolab·

15 Nov

NeuroVive Receives Vinnova Funding to Support Development of NV354: https://t.co/tqLc3eOtzW

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

10 Oct

NeuroVive Receives KL1333 Clinical Trial Regulatory Approval: https://t.co/rhM2e2fB7X

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

4 Oct

NeuroVive reports first NeuroSTAT clinical efficacy signal in traumatic brain injury (TBI): https://t.co/Yrt4i54q5z

Reply on Twitter Retweet on Twitter Like on Twitter1 Twitter

Maas Biolab @MaasBiolab·

6 Sep

NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan: https://t.co/rFHVtH8C5e

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

28 Aug

NeuroVive’s NVP015 program will be accelerated through award of major research grant to Children’s Hospital of Philadelphia: https://t.co/lHuixW86VK

Reply on Twitter Retweet on Twitter1 Like on Twitter2 Twitter

Maas Biolab @MaasBiolab·

9 Jul

NeuroVive’s Mitodrug "KL1333"-Works Better Than CoQ10 And Idebenone-Frontiers In Neurology: https://t.co/izEf4trEEt

Reply on Twitter Retweet on Twitter1 Like on Twitter3 Twitter

Maas Biolab @MaasBiolab·

6 Jul

NeuroVive’s Genetic Mitochondrial Disease Drug Candidate KL1333 Mechanism of Action Published in Scientific Journal: https://t.co/WxjxVpDwJw

Reply on Twitter Retweet on Twitter3 Like on Twitter4 Twitter

Maas Biolab @MaasBiolab·

18 Jun

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics: https://t.co/XVymbf6zuL

Reply on Twitter Retweet on Twitter Like on Twitter1 Twitter

Maas Biolab @MaasBiolab·

21 May

NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development: https://t.co/LQtf6SqtLk

Reply on Twitter Retweet on Twitter Like on Twitter Twitter